Literature DB >> 21630354

Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson's disease.

Meng-Ting Wang1, Pei-Wen Lian, Chin-Bin Yeh, Che-Hung Yen, Kao-Hsing Ma, Agnes L F Chan.   

Abstract

Empirical data regarding the choice of antipsychotics for the management of psychosis in patients with Parkinson's disease are limited. This study aimed to evaluate the incidence and prescribing patterns of antipsychotics and to determine the predictors associated with the prescribing of typical antipsychotics in patients with Parkinson's disease. This was a retrospective cohort study analyzing data from the National Health Insurance Research Database in Taiwan between January 1, 2000, and December 31, 2006, in which patients with Parkinson's disease (ICD-9-CM codes 332) initially receiving any antiparkinsonian drug (n = 2095) were followed up to evaluate the subsequent use of antipsychotics. Kaplan-Meier statistics and multiple logistic regression were employed to evaluate the cumulative probability of antipsychotic use and determinants of prescribing of typical antipsychotics, respectively. The cumulative probability of initiation of an antipsychotic within 6 years was found to be 51%, and the proportion of patients who began taking an atypical antipsychotic increased from 11.1% in 2001 to 36.1% in 2005. Physician specialty was found to be the most influential predictor of the prescribing of typical antipsychotics: physicians with an internal medicine specialty were 10.62 times more likely (95% confidence interval, 4.64-24.32) to prescribe typical antipsychotics than were neurologists. The use of antipsychotics in Parkinson's disease is common, and the use of typical antipsychotics dominates antipsychotic treatment. Particular attention needs to be paid to improving practice, including efforts that encourage primary care providers to have the appropriate choice of antipsychotics in patients with Parkinson's disease.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21630354     DOI: 10.1002/mds.23719

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

1.  Prevalence of and indications for antipsychotic use in Parkinson's disease.

Authors:  James H Bower; Brandon R Grossardt; Walter A Rocca; Rodolfo Savica
Journal:  Mov Disord       Date:  2017-12-26       Impact factor: 10.338

2.  High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study.

Authors:  Shin-Chia Tsai; Shiow-Yunn Sheu; Li-Nien Chien; Hsin-Chien Lee; Eunice Jia-Shiow Yuan; Rey-Yue Yuan
Journal:  Br J Clin Pharmacol       Date:  2018-06-19       Impact factor: 4.335

3.  Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

Authors:  Daniel Weintraub; Claire Chiang; Hyungjin Myra Kim; Jayne Wilkinson; Connie Marras; Barbara Stanislawski; Eugenia Mamikonyan; Helen C Kales
Journal:  JAMA Neurol       Date:  2016-05-01       Impact factor: 18.302

4.  Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study.

Authors:  Nathan Herrmann; Connie Marras; Hadas D Fischer; Xuesong Wang; Geoff M Anderson; Paula A Rochon
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

5.  Trends and Contributing Factors for Prescribing Antipsychotics in Newly Diagnosed Parkinson's Disease Patients: A Population-Based Study.

Authors:  Khalid Orayj
Journal:  Risk Manag Healthc Policy       Date:  2021-06-04

6.  Cardiovascular Events Associated with Antipsychotics in Newly Diagnosed Parkinson's Disease Patients: A Propensity Score Matched Cohort Study.

Authors:  Khalid Orayj
Journal:  Int J Gen Med       Date:  2021-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.